Gold is 2025’s best performer. UBS sees more upside
Waters Corporation (NYSE:WAT), a leader in analytical laboratory instruments and software solutions, is entering a new phase of growth following its strategic acquisition of Becton, Dickinson and Company’s (BDX) Biosciences & Dx business. This move has positioned the company for significant expansion in the pharmaceutical and biotechnology manufacturing sectors, prompting analysts to reassess its market potential and future prospects.
Company Overview and Recent Strategic Moves
Waters Corporation has long been focused on serving the pharmaceutical and biotechnology industries, with a particular emphasis on manufacturing processes. The company’s recent strategic acquisitions, including Halo Labs and Wyatt Technology, have bolstered its position in the biologics segment, which now accounts for approximately 20% of total revenue.
The most significant development, however, is the pending acquisition of BDX’s Biosciences & Dx business, expected to close by the end of the first quarter of 2026. This move is set to transform Waters from a primarily organic growth story to one with substantial M&A potential, potentially rivaling industry giants like Thermo Fisher Scientific (NYSE:TMO) and Danaher Corporation (NYSE:DHR).
Financial Performance and Outlook
The acquisition is expected to have a substantial impact on Waters’ financial profile. Analysts project that the company’s free cash flow will increase from approximately $700 million in fiscal year 2025 to $1.4 billion in fiscal year 2027. This robust cash generation, coupled with a strong balance sheet, could provide Waters with $2.5 billion to $5.0 billion in borrowing capacity for future growth initiatives.
Post-acquisition, Waters is anticipated to maintain adjusted EBITDA margins exceeding 31% while growing at a mid-single-digit to high-single-digit rate. The company’s current gross profit margin of 59.02% and return on equity of 37% demonstrate its operational efficiency. This performance is expected to outpace many of its large-cap peers, positioning the company favorably within the industry. For deeper insights into Waters’ financial health and growth potential, InvestingPro subscribers can access comprehensive analysis and additional metrics.
Market Position and Competitive Landscape
Waters’ expanded portfolio and enhanced market presence following the BDX acquisition are likely to strengthen its competitive position. The company currently trades at an EV/EBITDA multiple of 17.61x, with a P/E ratio of 26.23x. Analysts note that the company’s pro forma EV/EBITDA multiple of 15.0x for fiscal year 2026 represents an 18% discount to Thermo Fisher Scientific and a 25% discount to Danaher Corporation. To evaluate whether Waters represents a compelling investment opportunity, check our undervalued stocks list and access detailed valuation analysis through InvestingPro. This valuation gap suggests potential upside for Waters’ stock, particularly if the company can successfully integrate its acquisitions and capitalize on revenue synergies.
Industry Trends and Growth Drivers
Several key trends are supporting Waters’ growth trajectory. The biologics market, a significant focus area for the company, is projected to grow at a compound annual growth rate (CAGR) of 10.3% through 2028. Additionally, the GLP-1 treatments segment, where Waters has a strong presence, is expected to grow at a rate exceeding 25%.
The robust growth of India’s pharmaceutical industry, a key market for Waters, further supports the company’s conservative guidance and potential for outperformance. These industry tailwinds, combined with Waters’ strategic positioning, create a favorable environment for sustained growth.
Bear Case
How might integration challenges affect Waters’ performance post-acquisition?
The acquisition of BDX’s Biosciences & Dx business represents a significant expansion for Waters Corporation. While the potential benefits are substantial, integrating such a large business unit comes with inherent risks. Cultural differences, operational incompatibilities, and unforeseen complications could delay or diminish the expected synergies. If integration proves more challenging than anticipated, it may lead to temporary disruptions in operations, increased costs, or slower-than-expected realization of revenue synergies. This could potentially impact Waters’ financial performance in the short to medium term and erode investor confidence.
What risks does Waters face in executing its growth strategy?
Waters’ ambitious growth strategy, particularly its shift towards more aggressive M&A activity, exposes the company to execution risks. The company may face challenges in identifying and successfully completing future acquisitions that align with its strategic goals. Additionally, there’s a risk of overpaying for acquisitions in a competitive market, which could strain the company’s financial resources and potentially lead to goodwill impairments in the future. The company’s increased focus on the pharmaceutical and biotechnology sectors also heightens its exposure to industry-specific risks, such as regulatory changes or shifts in drug development trends, which could impact demand for its products and services.
Bull Case
How could Waters’ expanded product portfolio drive revenue synergies?
The acquisition of BDX’s Biosciences & Dx business significantly expands Waters’ product offerings, particularly in the biologics space. This broader portfolio allows Waters to offer more comprehensive solutions to its customers, potentially increasing its share of wallet within existing accounts. The company can leverage its expanded capabilities to cross-sell products and services, creating bundled offerings that provide greater value to customers and higher margins for Waters. Additionally, the combined expertise of Waters and the acquired BDX unit could lead to innovative new products that address unmet needs in the market, further driving revenue growth.
What potential does Waters have for further M&A activity given its improved financial position?
Waters’ improved financial position post-acquisition, with projected free cash flow growth to $1.4 billion by fiscal year 2027 and increased borrowing capacity of $2.5 billion to $5.0 billion, positions the company well for further strategic acquisitions. This financial strength allows Waters to pursue complementary businesses or technologies that could enhance its market position, expand its geographic reach, or add new capabilities to its portfolio. The company’s experience with integrating recent acquisitions like Halo Labs and Wyatt Technology provides a foundation for successfully executing and integrating future M&A deals, potentially accelerating Waters’ growth trajectory and solidifying its position as a leader in the life sciences tools and diagnostics sector.
SWOT Analysis
Strengths:
- Strong position in pharmaceutical and biotechnology manufacturing sectors
- Strategic acquisitions enhancing product portfolio and market presence
- Robust free cash flow generation and strong balance sheet
- Expertise in high-growth areas such as biologics and GLP-1 treatments
Weaknesses:
- Integration risks associated with large acquisitions
- Dependency on pharmaceutical and biotechnology sectors for growth
- Potential for execution challenges in new growth strategy
Opportunities:
- Expanding biologics market with projected 10.3% CAGR through 2028
- High growth in GLP-1 treatments segment
- Potential for further strategic M&A activity
- Revenue synergies from expanded product portfolio
Threats:
- Intense competition in the life sciences tools and diagnostics market
- Regulatory changes affecting pharmaceutical and biotechnology industries
- Potential for economic downturns impacting customer spending
- Rapid technological advancements requiring continuous innovation
Analysts Targets
- KeyBanc Capital Markets: $460.00 (August 18th, 2025)
- Barclays (LON:BARC) Capital Inc.: Rating suspended (July 15th, 2025)
- KeyBanc Capital Markets: $460.00 (June 2nd, 2025)
- Barclays Capital Inc.: $360.00 (May 7th, 2025)
- KeyBanc Capital Markets: $460.00 (March 31st, 2025)
- Barclays Capital Inc.: $400.00 (March 6th, 2025)
- Barclays Capital Inc.: $400.00 (February 13th, 2025)
- Barclays Capital Inc.: Upgraded to Equal Weight (February 10th, 2025)
This analysis is based on information available up to August 18, 2025, and reflects the market conditions and analyst perspectives as of that date.
InvestingPro: Smarter Decisions, Better Returns
Gain an edge in your investment decisions with InvestingPro’s in-depth analysis and exclusive insights on WAT. Our Pro platform offers fair value estimates, performance predictions, and risk assessments, along with additional tips and expert analysis. Explore WAT’s full potential at InvestingPro.
Should you invest in WAT right now? Consider this first:
Investing.com’s ProPicks, an AI-driven service trusted by over 130,000 paying members globally, provides easy-to-follow model portfolios designed for wealth accumulation. Curious if WAT is one of these AI-selected gems? Check out our ProPicks platform to find out and take your investment strategy to the next level.
To evaluate WAT further, use InvestingPro’s Fair Value tool for a comprehensive valuation based on various factors. You can also see if WAT appears on our undervalued or overvalued stock lists.
These tools provide a clearer picture of investment opportunities, enabling more informed decisions about where to allocate your funds.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.